

Resource Summary Report

Generated by [NIF](#) on Aug 29, 2026

Capan-2

RRID:CVCL_0026

Type: Cell Line

Proper Citation

RRID:CVCL_0026

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0026

Proper Citation: RRID:CVCL_0026

Description: Cell line Capan-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1630814](#), [PMID:1764370](#), [PMID:3019537](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7459858](#), [PMID:7809022](#), [PMID:7961102](#), [PMID:7972006](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:8426738](#), [PMID:10027410](#), [PMID:11169957](#), [PMID:11169959](#), [PMID:11668190](#), [PMID:12692724](#), [PMID:12800145](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:15770730](#), [PMID:16957166](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:24700732](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31037374](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Capan-2

Synonyms: CaPan-2, CAPAN-2, Capan 2, CAPAN 2, Capan2, CAPAN2

Cross References: BTO:BTO_0002745, CLO:CLO_0002198, EFO:EFO_0002154, MCCL:MCC:0000127, CLDB:cl642, CLDB:cl643, CLDB:cl644, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-80, BCRJ:0060, BioSample:SAMN03472025, BioSample:SAMN03473387, BioSample:SAMN10988212, cancercellines:CVCL_0026, CancerTools:161908, Cell_Model_Passport:SIDM00943, CGH-DB:163-1, CGH-DB:9270-4, ChEMBL-Cells:ChEMBL3308720, ChEMBL-Targets:ChEMBL1075417, CLS:300144, Cosmic:730527, Cosmic:736271, Cosmic:755303, Cosmic:808163, Cosmic:868246, Cosmic:910915, Cosmic:913303, Cosmic:922256, Cosmic:923167, Cosmic:932517, Cosmic:932987, Cosmic:933522, Cosmic:934554, Cosmic:947396, Cosmic:948727, Cosmic:949232, Cosmic:1006366, Cosmic:1108339, Cosmic:1299297, Cosmic:1320463, Cosmic:1366277, Cosmic:1571775, Cosmic:1995363, Cosmic:2009527, Cosmic:2046535, Cosmic:2434087, Cosmic:2668288, Cosmic-CLP:910915, DepMap:ACH-000107, DSMZ:ACC-245, DSMZCellDive:ACC-245, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910915, GEO:GSM206453, GEO:GSM621896, GEO:GSM784710, GEO:GSM886921, GEO:GSM887987, GEO:GSM1024399, GEO:GSM1374440, GEO:GSM1669664, GEO:GSM7701427, GEO:GSM7701428, IARC_TP53:313, IARC_TP53:21042, IARC_TP53:30199, IGRhCellID:Capan2, IZSLER:BS TCL 10, KCLB:30080, LiGeA:CCLE_178, LINCS_LDP:LCL-1733, Lonza:1464, MetaboLights:MTBLS812, PharmacDB:Capan2_185_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0026, PubChem_Cell_line:CVCL_0026, SKY/M-FISH/CGH:1993, Wikidata:Q54808591

ID: CVCL_0026

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260829T231749+0000

Ratings and Alerts

No rating or validation information has been found for Capan-2.

No alerts have been found for Capan-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 298 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Farooq MA, et al. (2026) TIPE2 knockdown enhances the anti-tumor efficacy of NKG2D CAR-T cells against pancreatic cancer via activating NF- κ B signaling pathway. Journal of

translational medicine, 24(1).

Yadav K, et al. (2026) Therapeutic targeting of GSK-3 β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ-2412, a novel sunitinib analogue. *British journal of pharmacology*, 183(15), 4196.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. *Cell reports. Medicine*, 7(4), 102688.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. *Communications biology*, 9(1).

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Drouillard D, et al. (2026) Mutant KRAS promotes NF- κ B driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for biology*.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8 $^{+}$ T cell infiltration in pancreatic ductal adenocarcinoma. *iScience*, 29(7), 116500.

Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD $^{+}$ -Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD $^{+}$ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. *Cell*, 189(6), 1731.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Zhu L, et al. (2026) The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. *Drug design, development and therapy*, 20, 568551.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

N'Guessan É, et al. (2025) Comparative theranostic efficacy of ^{177}Lu - and ^{161}Tb -labeled A1K2 SdAb in mesothelin-positive tumors. *European journal of nuclear medicine and molecular imaging*.

Tantawi H, et al. (2025) A Nucleoside Analogue Featuring a C3'-Stereogenic All-Carbon Quaternary Center as a Bioenergetic Disruptor of KRAS-Mutated Pancreatic Cancer Cells. *ACS medicinal chemistry letters*, 16(9), 1814.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. *Nature communications*, 16(1), 9996.

Raymakers L, et al. (2025) The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. *Cells*, 14(9).

Inthanachai T, et al. (2025) Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. *Journal for immunotherapy of cancer*, 13(1).

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.